Wantai Bio: Nine-valent HPV vaccine approved for marketing
2025-06-04 07:32:43
On June 4th, Wantai Biotechnology announced that the nine-valent human papillomavirus vaccine (Escherichia coli) (trade name: Xinkening 9) declared by Xiamen Wantai Canghai Biotechnology Co., Ltd., a wholly-owned subsidiary of the company, has been approved for marketing. The vaccine is suitable for women aged 9-45. Among them, 9-17 years old can use the two-dose vaccination procedure, and 18-45 years old can use the three-dose vaccination procedure. Previously, only one nine-valent HPV vaccine was listed in the world, which was Merck's Jiadaxiu ® 9.
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
